- Home
- SDHY vs AQST Comparison
SDHY vs AQST Comparison
Compare SDHY & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SDHY
- AQST
- Stock Information
- Founded
- SDHY 2020
- AQST 2004
- Country
- SDHY United States
- AQST United States
- Employees
- SDHY N/A
- AQST N/A
- Industry
- SDHY Finance/Investors Services
- AQST Biotechnology: Pharmaceutical Preparations
- Sector
- SDHY Finance
- AQST Health Care
- Exchange
- SDHY Nasdaq
- AQST Nasdaq
- Market Cap
- SDHY 415.2M
- AQST 390.4M
- IPO Year
- SDHY N/A
- AQST 2018
- Fundamental
- Price
- SDHY $16.98
- AQST $5.08
- Analyst Decision
- SDHY
- AQST Strong Buy
- Analyst Count
- SDHY 0
- AQST 7
- Target Price
- SDHY N/A
- AQST $10.29
- AVG Volume (30 Days)
- SDHY 94.0K
- AQST 2.6M
- Earning Date
- SDHY 01-01-0001
- AQST 11-03-2025
- Dividend Yield
- SDHY 8.46%
- AQST N/A
- EPS Growth
- SDHY N/A
- AQST N/A
- EPS
- SDHY 1.07
- AQST N/A
- Revenue
- SDHY N/A
- AQST $44,132,000.00
- Revenue This Year
- SDHY N/A
- AQST N/A
- Revenue Next Year
- SDHY N/A
- AQST $38.71
- P/E Ratio
- SDHY $14.31
- AQST N/A
- Revenue Growth
- SDHY N/A
- AQST N/A
- 52 Week Low
- SDHY $13.93
- AQST $2.12
- 52 Week High
- SDHY $15.50
- AQST $5.80
- Technical
- Relative Strength Index (RSI)
- SDHY 53.57
- AQST 67.17
- Support Level
- SDHY $16.89
- AQST $4.75
- Resistance Level
- SDHY $17.18
- AQST $5.60
- Average True Range (ATR)
- SDHY 0.10
- AQST 0.29
- MACD
- SDHY -0.00
- AQST 0.10
- Stochastic Oscillator
- SDHY 43.66
- AQST 72.49
About SDHY PGIM Short Duration High Yield Opportunities Fund
PGIM Short Duration High Yield Opportunities is a closed-end management investment company. The fund's investment objective is to provide total return, through a combination of current income and capital appreciation. Its seeks to achieve its objective by investing in a diversified portfolio of high yield fixed income instruments.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.